Industry news

BDO Special Report: PE Deal Activity in Healthcare

BDO USA

“Outpatient services will play an increasingly large role in healthcare delivery moving forward, as payers and providers aim to deliver quality care in the lowest-cost settings as site neutrality provisions begin to take hold. Reimbursements for healthcare providers are increasingly tied to patient outcomes, as well as treating patients in the right place at the right time, so collaboration among hospitals and niche providers is critical in this new environment. Partnerships, joint ventures, deployment of telemedicine where appropriate and other collaborative business models are essential to success.” - Patrick Pilch, managing director and Healthcare Advisory practice leader with The BDO Center for Healthcare Excellence & Innovation.

Med tech companies gain from Big Pharma's pain over drug price increases

Emily Wasserman / FierceMedicalDevices

The rising cost of prescription drugs has just about everyone up in arms, with lawmakers, presidential hopefuls such as Hillary Clinton and the public criticizing companies' prices hikes for certain meds. As the chorus of discontent reaches a crescendo, devicemakers are benefiting from the noise.

Google Life Sciences CMO opens up about research plans

Emily Wasserman / FierceMedicalDevices

Back in May, Alphabet's ($GOOG) Google Life Sciences brought on then-Harvard cardiologist Jessica Mega to lead its Baseline study, a research effort aimed at gathering molecular and genetic data to jump-start medical research and offer a more comprehensive look at human health. Now Mega is opening up about the study, revealing more about the company's plans to harness data to address and potentially prevent disease.

Biotech Sector on Track to Close Year in Positive Territory

Peter Winter / Thomson Reuters BioWorld

Biotech investors had a great deal to be thankful for heading into the Thanksgiving holiday. With just one month to go before biotech closes the curtains on another year, the sector appears to be back on track and stands poised to finish 2015 in positive territory, a performance which is much better than some pundits were predicting when valuations nosedived during August and September as the heated debate over drug prices got into high gear.

Cancer drug prices vary widely across Europe, study finds

Ben Hirschler / Reuters

The cost of cancer drugs varies substantially across Europe, experts said on Friday in a new analysis that is likely to fuel debate about the rising cost of modern medicines.

Generic drugs face April 2016 price caps in Japan

EJ Lane / FeircePharmaAsia

If Japanese health officials follow through on current plans, beginning in April of next year makers of generic drugs that until now have enjoyed the government's strong backing will face their own price caps, reportedly a reduction of about 17% from current levels.

Medtech stocks benefit as drug-pricing scrutiny intensifies

Lewis Krauskopf / Reuters

Investors have been moving into medical device shares as a safer play in the healthcare sector amid concerns that intensifying scrutiny over high U.S. prescription drug prices will continue to weigh on pharmaceutical and biotech stocks.

03 December 2015

Marinus Pharmaceuticals Bolsters Clinical and Regulatory Expertise

Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the hiring of Jaakko Lappalainen, M.D., Ph.D., as Vice President of Clinical Development and Kimberly A. McCormick, PharmD, as Head of Regulatory Affairs. Dr. Lappalainen has 10 years of experience in the design, monitoring, interpretation and reporting of clinical trials at pharmaceutical research and development companies, including AstraZeneca. Dr. McCormick has more than 15 years of regulatory strategy and submissions experience at major pharmaceutical firms, including Shire and Pfizer. 

Beijing aims to refill medicine chest with "Made in China" drugs

By Ben Hirschler and Adam Jourdan / Reutrers

China, already a global powerhouse in high-tech areas from solar panels to bullet trains, is turning its industrial might to the challenge of making more of its own drugs for a vast and ageing population.

Top Investor Tuesday — Healthcare IPOs

PitchBook Blog

Healthcare has become an increasingly intriguing investment for VCs lately—even Andreessen Horowitz is entering the space. Reasons for this surely include the lucrative exits seen within the healthcare sector during the past few years. Since 2013, more than 250 VC-backed healthcare companies have exited via an IPO alone, bringing healthy returns to the 556 VC investors that backed them. Through those public offerings, more than $17.6 billion was raised.